This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the INLYTA® (axitinib​​​​​​​) Summary of Product Characteristics for Great Britain. 
​​​​​​​
Prescribing Information for INLYTA® (axitinib) click here.  Adverse event reporting information can be found at the bottom of the page.

Dosing 

The recommended starting dose is 5 mg twice daily, given orally.1

​​​​​​​Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs that cannot be managed by concomitant medicinal products or dose adjustments.

If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.

​​​​​​​How to take INLYTA®

The dose of INLYTA® can be increased or decreased in the absence or presence of adverse events (AE)1

Dose Increase1:
Patients who tolerate the starting dose of 5 mg twice daily with no adverse reactions > grade 2 for two consecutive weeks may have their dose increased to 7 mg twice daily unless:

  • The patient's blood pressure is >150/90 mm Hg, or the patient is receiving antihypertensive treatment
​​Subsequently, using the same criteria, patients who tolerate a dose of 7 mg twice daily may have their dose increased to a maximum of 10 mg twice daily.

Dose Reduction1:
When dose reduction is necessary, the dose may be reduced to 3mg twice daily and further to 2 mg twice daily.​​​​​​​
​​​​​​​

Available Doses 

INLYTA® is available in 4 dose strengths to facilitate dose modification. 

•     1 mg
•     3 mg
•     5 mg 
•     7 mg

​​​INLYTA® Dosing​​​​​​​

†If a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease from 5 mg BID to 2 mg BID is recommended. If a strong CYP3A4/5 inducer must be co-administered, a dose increase is recommended and patients should be monitored for toxicities.1


References
  1. INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA® Summary of Product Characteristics for Northern Ireland click here.
PP-INL-GBR-0813. February 2022

Indication

  • INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine1

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?